Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Tronieri reports receiving an investigator-initiated grant, on behalf of the University of Pennsylvania, from Novo Nordisk and receiving consulting fees from Currax Pharmaceuticals, LLC
2 In the full study population, breast cancer was diagnosed in 1.62% (247/15,264) of women with GLP-1 exposure compared with 2.47% (2,381/96,382) of women without exposure, corresponding to an odds ratio (OR) of 0.649 (95% CI, 0.5690.741
This data point is notable for two reasons: It suggests that oral GLP-1 receptor activation can sustain metabolic effects achieved by injectable therapy It addresses a real-world concern regarding treatment transitions, which are common due to availability, cost, or patient preference Importantly, Lilly did not claim superiority over semaglutide
doi:10.1007/s11095-012-0917-z 179
Emerging role of ferroptosis in diabetic kidney disease: molecular mechanisms and therapeutic opportunities
